103 related articles for article (PubMed ID: 8471427)
1. Gallium-67 radiotoxicity in human U937 lymphoma cells.
Jonkhoff AR; Huijgens PC; Versteegh RT; van Dieren EB; Ossenkoppele GJ; Martens HJ; Teule GJ
Br J Cancer; 1993 Apr; 67(4):693-700. PubMed ID: 8471427
[TBL] [Abstract][Full Text] [Related]
2. Biological effectiveness of 67-gallium decay in HL60 cells compared with external low dose rate gamma irradiation: effects on proliferation, G2 arrest, and clonogenic capacity.
Jonkhoff AR; von Dieren EB; Huijgens PC; Versteegh RT; Dräger A; vd Loosdrecht AA; Teule GJ
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):117-24. PubMed ID: 8083104
[TBL] [Abstract][Full Text] [Related]
3. Radiotoxicity of 67-gallium on myeloid leukemic blasts.
Jonkhoff AR; Huijgens PC; Versteegh RT; van Lingen A; Ossenkoppele GJ; Dräger AM; Teule GJ
Leuk Res; 1995 Mar; 19(3):169-74. PubMed ID: 7700078
[TBL] [Abstract][Full Text] [Related]
4. Gallium 67 in the human lymphoid cell line U-715: uptake, cytotoxicity and intracellular localization.
van Leeuwen-Stok AE; Dräger AM; Schuurhuis GJ; Platier AW; Teule GJ; Huijgens PC
Int J Radiat Biol; 1993 Dec; 64(6):749-59. PubMed ID: 7903343
[TBL] [Abstract][Full Text] [Related]
5. Radiotoxic effect and dosimetry of 67GA in multicellular spheroids as compared to single cells of the lymphoma cell line U715.
van Leeuwen-Stok AE; Schuurhuis GJ; Dräger Am; Visser-Platier AW; van Dieren EB; Teule GJ; Huijgens PC
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):507-17. PubMed ID: 8655374
[TBL] [Abstract][Full Text] [Related]
6. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
7. High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study.
Jonkhoff AR; Plaizier MA; Ossenkoppele GJ; Teule GJ; Huijgens PC
Br J Cancer; 1995 Dec; 72(6):1541-6. PubMed ID: 8519674
[TBL] [Abstract][Full Text] [Related]
8. Targeting and therapy of human glioma xenografts in vivo utilizing radiolabeled antibodies.
Williams JA; Wessels BW; Edwards JA; Kopher KA; Wanek PM; Wharam MD; Order SE; Klein JL
Cancer Res; 1990 Feb; 50(3 Suppl):974s-979s. PubMed ID: 2404587
[TBL] [Abstract][Full Text] [Related]
9. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
Govindan SV; Goldenberg DM; Elsamra SE; Griffiths GL; Ong GL; Brechbiel MW; Burton J; Sgouros G; Mattes MJ
J Nucl Med; 2000 Dec; 41(12):2089-97. PubMed ID: 11138697
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4.
Schmidberger H; Buchsbaum DJ; Blazar BR; Everson P; Vallera DA
Cancer Res; 1991 Apr; 51(7):1883-90. PubMed ID: 2004371
[TBL] [Abstract][Full Text] [Related]
11. Effect of modulation of the transferrin receptor on gallium-67 uptake and cytotoxicity in lymphoma cell lines.
van Leeuwen-Stok AE; Schuurhuis GJ; Dräger AM; Visser-Platier AW; Teule GJ; Huijgens PC
Br J Cancer; 1996 Aug; 74(4):619-24. PubMed ID: 8761380
[TBL] [Abstract][Full Text] [Related]
12. Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice.
Morton BA; Beatty BG; Mison AP; Wanek PM; Beatty JD
Cancer Res; 1990 Feb; 50(3 Suppl):1008s-1010s. PubMed ID: 2297712
[TBL] [Abstract][Full Text] [Related]
13. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle dependency of 67gallium uptake and cytotoxicity in human cell lines of hematological malignancies.
Van Leeuwen-Stok EA; Jonkhoff AR; Visser-Platier AW; Dräger LM; Teule GJ; Huijgens PC; Schuurhuis GJ
Leuk Lymphoma; 1998 Nov; 31(5-6):533-44. PubMed ID: 9922043
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
[TBL] [Abstract][Full Text] [Related]
16. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma.
Gasparini M; Bombardieri E; Castellani M; Tondini C; Maffioli L; Devizzi L; Gerundini P
J Nucl Med; 1998 Sep; 39(9):1586-90. PubMed ID: 9744348
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
Michel RB; Andrews PM; Rosario AV; Goldenberg DM; Mattes MJ
Nucl Med Biol; 2005 Apr; 32(3):269-78. PubMed ID: 15820762
[TBL] [Abstract][Full Text] [Related]
19. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.
Ochakovskaya R; Osorio L; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jun; 7(6):1505-10. PubMed ID: 11410483
[TBL] [Abstract][Full Text] [Related]
20. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
